Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2020 / Cilt: 30 - Sayı: 3

Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?

Pages
162–170
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To determine the relationship between 18F FDG PET/CT parameters of the primary tumor/nodal metastasis/distant metastasis and overall survival (OS) of patients with newly diagnosed non-small cell lung cancer (NSCLC).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To determine the relationship between 18F FDG PET/CT parameters of the primary tumor/nodal metastasis/distant metastasis and overall survival (OS) of patients with newly diagnosed non-small cell lung cancer (NSCLC).
📊
Key Findings & Data:Data from 159 patients with newly diagnosed NSCLC who underwent pretreatment 18F FDG PET/CT were analyzed.
💡
Conclusion & Impact:Independent predictors for OS were found as SUVmaxN in the group of patients with distant metastasis, and SUVmax, MTV of the primary tumor (MTVT), and lymph node size (LNsize) in the group of patients without distant metastasis. 18F FDG PET/CT may distinguish patients with high risk for poor prognosis in patients with and without metastasis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

To determine the relationship between 18F FDG PET/CT parameters of the primary tumor/nodal metastasis/distant metastasis and overall survival (OS) of patients with newly diagnosed non-small cell lung cancer (NSCLC). Data from 159 patients with newly diagnosed NSCLC who underwent pretreatment 18F FDG PET/CT were analyzed. The SUVmax, SUVmean, the metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor, lymph node metastasis, and distant metastasis were measured. The total MTV and total TLG were calculated. The optimal cut-off values of the 18F FDG PET/CT parameters were determined using receiver operating characteristics curve analysis. Kaplan-Meier curves were used to determine OS. There were a total of 101 deaths during the follow-up (range, 3.7-54.2 months). The median OS was 26.4 months for the entire group, 11.8 months for patients with metastasis, and 41 months for patients with no metastasis (p< 0.001). In all patients (n= 159), nodal SUVmax (SUVmaxN), total TLG, and the presence of distant metastasis were independent predictors. The 2-year OS for patients with TLG ≥ 328 and TLG < 328 were 32% and 80%, respectively. Independent predictors for OS were found as SUVmaxN in the group of patients with distant metastasis, and SUVmax, MTV of the primary tumor (MTVT), and lymph node size (LNsize) in the group of patients without distant metastasis. 18F FDG PET/CT may distinguish patients with high risk for poor prognosis in patients with and without metastasis.

🔖

Cite This Article

KUPIK, O., BOZKURT, M., ASA, S., EREN, G., GUNDOGDU, H., ARPA, M. (2020). Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 30 - Sayı: 3, 162–170. https://ajindex.com/articles/323251

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010
  2. UyBico SJ, Wu CC, Suh RD, et al. Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30: 1163-1181, 2010
  3. Ruilong Z, Daohai X, Li G, et al. Diagnostic value of 18F-FDGPET/ CT for the evaluation of solitary pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun 38: 67-75, 2017
  4. Huellner MW, de Galiza Barbosa F, Husmann L, et al. TNM staging of non–small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med 57: 21-26, 2016
  5. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50 Suppl 1: 31S-42S, 2019. 6. van den Berg LL, Klinkenberg TJ, Groen HJ, et al. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol 10: 826-831, 2015
  6. Sheikhbahaei S, Mena E, Yanamadala A, et al. The value of FDG PET/CT in treatment response assessment, follow-up, and surveillance of lung cancer. AJR Am J Roentgenol 208: 420-433, 2017
  7. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41: 1533-1541, 2005
  8. Jeong HJ, Min JJ, Park J, et al. Determination of the prognostic value of [18F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23: 865-870, 2002
  9. Imamura Y, Azuma K, Kurata S, et al. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer 71: 49-54, 2011
  10. Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 39: 27-38, 2012
  11. Agrawal V, Coroller T, Hou Y, et al. Mediastinal lymph node olvume is associated with locoregional recurrence and overall survival in stage IIIA-IIIB Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 96: E451, 2016
  12. Pöttgen C, Levegrün S, Theegarten D, et al. Value of 18Ffluoro- 2-deoxy-D-glucose-positron emission tomography/ computed tomography in non–small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12: